

This announcement is for information purposes only and does not constitute an invitation or solicitation of an offer to acquire, purchase or subscribe for securities or an invitation to enter into an agreement to do any such things, nor is it calculated to invite any offer to acquire, purchase or subscribe for any securities.

This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia).

*This announcement and the information herein do not constitute or form a part of any offer or solicitation to purchase, subscribe or sell securities in the United States. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “**Securities Act**”), or the securities laws of any state of the United States or other jurisdiction. The securities referred to herein will be offered and sold outside the United States in offshore transactions in reliance on Regulation S under the Securities Act (the “**Regulation S**”) and may not be offered or sold within the United States absent registration or an applicable exemption from registration under the Securities Act. No public offering of the securities referred to herein is being made in the United States or in any other jurisdiction where such an offering is restricted or prohibited. Any public offering of securities in the United States will be made by means of a prospectus. Such prospectus will contain detailed information about the company making the offer, its management, as well as financial statements. The Issuer and the Company do not intend to make any public offering of securities in the United States. No money, securities or other consideration is being solicited by this announcement or the information contained herein and, if sent in response to this announcement or the information contained herein, will not be accepted.*



VIVA BIOTECH HOLDINGS

维亚生物科技控股集团

(Incorporated in the Cayman Islands as an exempted company with limited liability)

(Stock code: 1873)

COMPLETION OF THE ISSUE OF US\$280 MILLION 1.00 PER CENT GUARANTEED CONVERTIBLE BONDS DUE 2025

Reference is made to the announcement of Viva Biotech Holdings (the “**Company**”) dated December 18, 2020 in relation to the proposed issue of the Bonds (the “**Announcement**”). Unless otherwise defined, all terms used herein shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that all the conditions precedent under the Subscription Agreement have been satisfied and/or waived and the issue of the Bonds in an aggregate principal amount of US\$280 million was completed on December 30, 2020.

Application has been made to The Stock Exchange of Hong Kong Limited for the listing of and permission to deal in the Bonds by way of debt issues to professional investors (as defined in Chapter 37 of the Listing Rules) only, as described in the offering circular relating thereto dated December 28, 2020. Permission for the listing of, and dealing in the Bonds is expected to become effective on December 31, 2020.

By Order of the Board
Viva Biotech Holdings
Mr. Mao Chen Cheney
Chairman

Hong Kong, December 30, 2020

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Mao Chen Cheney (Chairman), Mr. Wu Ying, Mr. Hua Fengmao and Mr. Ren Delin; a non-executive Director, namely, Ms. Sun Yanyan; and three independent non-executive Directors, namely, Mr. Fu Lei, Ms. Li Xiangrong and Mr. Wang Haiguang.